EGCG对乙酸诱导大鼠结肠炎的治疗作用及抗氧化机制  

Therapeutic effect and antioxidation mechanism of epigallocatechin-3-gallate in rats with colitis induced by acetic acid

作　　者：冉志华[1] 陈迟[1] 萧树东[1] 

机构地区：[1]上海交通大学医学院附属仁济医院消化内科上海市消化疾病研究所,上海市200001

出　　处：《世界华人消化杂志》2007年第4期359-364,共6页World Chinese Journal of Digestology

基　　金：上海市重点学科建设资助项目;No.Y0205

摘　　要：目的:在大鼠结肠炎的模型中,研究表没食子儿茶素没食子酸酯(epigallocatechin-3-gallate, EGCG)的治疗作用及其抗氧化损伤作用的机制．方法:SD大鼠60只,随机分为正常对照组(n =10)、模型安慰剂组(n=20)、EGCG治疗组(n=15)、柳氮磺吡啶(SASP)治疗组(n= 15)．正常组常规饲养,模型安慰剂组、EGCG组、SASP组80 g/L乙酸造模后分别予以生理盐水2 mL/d、EGCG 50 mg/(kg·d)、SASP 0．25 g/(kg·d)灌胃治疗7 d,观察大鼠活动状态,进食量,体质量,大便性状,大便出血情况,计算疾病活动指数(DAI),判断疗效．第8天处死大鼠并进行结肠黏膜损伤指数(CMDI)评分,组织学评级,测定组织一氧化氮自由基(NO)、脂质过氧化产物丙二醛(MDA)以及超氧化物歧化酶(SOD)含量．结果:与模型安慰剂组相比,EGCG显著改善DAI(1．1±0．9 vs 3．9±0．4,P＜0．01)、CMDI(1．5±0．9 vs 3．3±0．6,P＜0．05)和组织学评级(4．6±3．1 vs 9．3±2．8,P＜0．01)．与SASP组相比, EGCG显著改善DAI(1．1±0．9 vs 3．0±1．2, P＜0．01)、CMDI(1．5±0．9 vs 2．3±0．9,P＜0．05)和组织学评级(4．6±3．1 vs 7．9±4．0,P＜0．05)．与模型安慰剂组相比,EGCG组NO含量显著下降(9．1±5．6μmol/g vs 15．4±5．0μmol/g, P＜0．05),MDA含量也显著下降(0．9±0．6μmol/g vs 1．5±0．6μmol/g,P＜0．05),SOD含量显著提高(3090．6±568．4 nkat/mg vs 1373．6±410．1 nkat/mg,P＜0．05)．与SASP组相比,EGCG组SOD含量显著提高(3090．6±568．4 nkat/mg vs 1268．6±43 1．8 nkat/mjz,P＜0．05)．结论:EGCG可通过抑制氧化损伤减轻结肠炎症反应．且疗效优于传统药物SASP．AIM： To investigate the therapeutic effect and antioxidation mechanism of epigallocatechin-3- gallate （EGCG） in rats with acetic acid-induced colitis. METHODS： Sixty male rats were randomly assigned into 4 groups： normal control （n = 10）, model placebo （n = 20）, EGCG （n= 15）, sulfasalazine （SASP, n = 15）. The rats in normal group were treated with regular feeding, while those in the other three groups were treated orally with normal saline （2 mL/d）, EGCG [50 mg/（kg · d）], and SASP [0.25 g（kg · d）] respectively for 7 days after the colitis model was induced by 80 g/L acetic acid. The general condition, food intake, weight, stool consistency, and bloody stool were observed, and then the disease activity index （DAI） and the therapeutic effects were evalu-ated. All the rats were sacrificed on day 8. The colon mucosal damage index （CMDI）, and histological scores were evaluated and the tissue contents of nitric oxide （NO）, malondialdehyde （MDA）, superoxide dismutase （SOD） were measured as well. RESULTS： As compared with the placebo and SASP, EGCG notably improved the DAI （1.1 ± 0.9 vs 3.9 0.4, 3.0 1.2, P 〈 0.01）, CMDI （1.5 0.9 vs 3.3 0.6, 2.3 0.9, P 〈 0.05） and histological scores （4.6 3.1 vs 9.3 2.8, 7.9 4.0, P 〈 0.01）. In comparison with those in model placebo group, the levels of NO and MDA in EGCG group were significantly reduced （NO： 9.1 5.6 μmol/g vs 15.4 5.0 μmol/g, P 〈 0.05; MDA： 0.9 0.6 μmol/g vs 1.5 0.6 μmol/g, P 〈 0.05）, while the level of SOD was increased remarkably （3090.6 ± 568.4 nkat/mg vs 1373.6 ±410.1 nkat/mg, P 〈 0.05）. Besides, the level of SOD was remarkably higher in EGCG group than that in SASP group （3090.6 ±568.4 nkat/mg vs 1268.6 ± 431.8 nkat/ mg, P 〈 0.05）. CONCLUSION： EGCG may ameliorate the inflammatory reactions in Colitis by its antioxidative activity, and its therapeutic effect is superior to that of the conventional medicine SASP.

关 键 词：表没食子儿茶素没食子酸酯 结肠炎 抗氧化 机制 

分 类 号：R574.62[医药卫生—消化系统]